Yves Benoit
Ghent University Hospital
143 Papers
1K Citations
Yves Benoit is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Leukemia & Medicine. The author has an hindex of 37, co-authored 139 publications. Previous affiliations of Yves Benoit include Memorial Hospital of South Bend.
Chat about Author
Papers
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
Michel Duval,Stefan Suciu,Alina Ferster,Xavier Rialland,Brigitte Nelken,Patrick Lutz,Yves Benoit,Alain Robert,Anne-Marie Manel,Etienne Vilmer,Jacques Otten,N Philippe +11 more
TL;DR: With the dose scheduling used in this protocol, E coli-asparaginase induced more coagulation abnormalities but was superior to Erwinia-asParaginase for the treatment of childhood lymphoid malignancies.
431
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
Monika Brüggemann,André Schrauder,Thorsten Raff,Heike Pfeifer,Michael Dworzak,Oliver G. Ottmann,Vahid Asnafi,André Baruchel,Renato Bassan,Yves Benoit,Andrea Biondi,Hélène Cavé,Hervé Dombret,Adele K. Fielding,Robert Foa,Nicola Gökbuget,Ah Goldstone,Nicholas Goulden,Günter Henze,Dieter Hoelzer,G. E. Janka-Schaub,Elizabeth Macintyre,Rob Pieters,Alessandro Rambaldi,Josep-Maria Ribera,Kjeld Schmiegelow,Orietta Spinelli,Jan Stary,A von Stackelberg,Michael Kneba,Martin Schrappe,J. J. M. Van Dongen +31 more
TL;DR: A panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials.
371
PHF6 mutations in T-cell acute lymphoblastic leukemia
Pieter Van Vlierberghe,Pieter Van Vlierberghe,Pieter Van Vlierberghe,Teresa Palomero,Hossein Khiabanian,Joni Van der Meulen,Mireia Castillo,Nadine Van Roy,Barbara De Moerloose,Jan Philippé,Sara González-García,María L. Toribio,Tom Taghon,Linda Zuurbier,Barbara Cauwelier,Christine J. Harrison,Claire Schwab,Markus Pisecker,Sabine Strehl,Anton W. Langerak,Jozef Gecz,Edwin Sonneveld,Rob Pieters,Elisabeth Paietta,Jacob M. Rowe,Peter H. Wiernik,Yves Benoit,Jean Soulier,Bruce Poppe,Xiaopan Yao,Carlos Cordon-Cardo,Jules P.P. Meijerink,Raul Rabadan,Frank Speleman,Adolfo A. Ferrando +34 more
TL;DR: PHF6 is identified as a new X-linked tumor suppressor in T-ALL and a strong genetic interaction between PHF6 loss and aberrant expression of TLX transcription factors in the pathogenesis of this disease is pointed to.
314
Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005
Maurizio Aricò,Martin Schrappe,Stephen P. Hunger,William L. Carroll,Valentino Conter,Stefania Galimberti,Atsushi Manabe,Vaskar Saha,André Baruchel,Kim Vettenranta,Keizo Horibe,Yves Benoit,Rob Pieters,Gabriele Escherich,Lewis B. Silverman,Ching-Hon Pui,Maria Grazia Valsecchi +16 more
TL;DR: Clinical outcome of children and adolescents with Ph-positive ALL has improved with advances in transplantation and chemotherapy, and transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone.
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Sofie Peirs,Filip Matthijssens,Steven Goossens,Inge Van de Walle,Katia Ruggero,Charles E. de Bock,Sandrine Degryse,Kirsten Canté-Barrett,Delphine Briot,Emmanuelle Clappier,Tim Lammens,Barbara De Moerloose,Yves Benoit,Bruce Poppe,Jules P.P. Meijerink,Jan Cools,Jean Soulier,Terence H. Rabbitts,Tom Taghon,Franki Speleman,Pieter Van Vlierberghe +20 more
TL;DR: In this article, the authors evaluated B-cell lymphoma (BCL)-2 inhibition by the BH3 mimetic ABT-199 as a new therapeutic strategy in human T-ALL.
228